Summary by Futu AI
On September 30, 2024, a group of related entities including GV 2019, L.P., GV 2019 GP, L.P., GV 2019 GP, L.L.C., GV 2021, L.P., GV 2021 GP, L.P., GV 2021 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc., and Alphabet Inc., collectively known as the Reporting Persons, filed an amendment with the United States Securities and Exchange Commission to report that they have ceased to be beneficial owners of more than 5% of Invivyd, Inc.'s common stock. This amendment, identified as Schedule 13G/A, indicates that as of September 30, 2024, the Reporting Persons collectively own 0.0% of Invivyd's issued common stock, which is calculated based on 119,442,635 shares outstanding as of August 1, 2024. The initial statement was filed on February 14, 2022, and this recent amendment confirms the change in ownership status. Invivyd, Inc., formerly known as Adagio Therapeutics, Inc., is headquartered in Waltham, MA, and the Reporting Persons are associated with entities organized in Delaware, with a principal business office located at 1600 Amphitheatre Parkway, Mountain View, CA.